<DOC>
	<DOCNO>NCT00329745</DOCNO>
	<brief_summary>This Year 3 extension main study rota-028 , 029 030 conducted evaluate vaccine efficacy severe rotavirus ( RV ) gastroenteritis ( GE ) third year life infant previously vaccinate human rotavirus ( HRV ) vaccine placebo follow schedule : 3 4 month age study rota-028 ; 2 4 month age study rota-029 rota-030 . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Year 3 Extension Efficacy Follow-up Subjects Vaccinated Studies Rota-028 , 029 030 ( NCT00197210 )</brief_title>
	<detailed_description>Note new subject recruit extension phase study . The expected total enrolment primary study follow : rota-028 : 5700 rota-029 : 3018 rota-030 : 1102</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include , 6 12 week age Hong Kong Taiwan 11 17 week age Singapore time first vaccination accord country recommendation routine vaccination schedule . Written inform consent obtain parent guardian subject , prior study procedure . Free obvious health problem establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine placebo , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Child unlikely remain study area duration study Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbated component vaccine . Administration immunoglobulins and/or blood product since birth plan administration study period . Oral intake immunoglobulin allow . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation gastrointestinal tract serious medical condition determine investigator . First second degree consanguinity parent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rotavirus Gastroenteritis</keyword>
	<keyword>Human rotavirus vaccine , efficacy , infant</keyword>
</DOC>